Robuta

https://www.biospace.com/mindmed-to-participate-at-the-lifesci-partners-11th-annual-corporate-access-event MindMed to Participate at the LifeSci Partners 11th Annual Corporate Access Event - BioSpace Dec 30, 2021 - Mind Medicine today announced that MindMed's Chief Executive Officer and Director, Robert Barrow , will be participating in a panel and in one-on-one investor... https://www.newswire.ca/news-releases/mindmed-files-final-prospectus-in-connection-with-bought-deal-equity-financing-865676693.html MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ) ("MindMed" or the "Company") is pleased to announce that further to its previously... bought dealmindmedfilesfinalprospectus https://www.prnewswire.com/news-releases/mindmed-receives-fda-type-c-meeting-response-for-project-lucy-phase-2b-clinical-trial-301292298.html MindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading clinical stage psychedelic medicine company, announces receipt of Type C Meeting... https://www.macrotrends.net/stocks/charts/MNMD/mind-medicine-mindmed/stock-splits Mind Medicine (MindMed) - 10 Year Stock Split History | MNMD | MacroTrends Stock split history for Mind Medicine (MindMed) since 2016. Prices shown are actual historical values and are not adjusted for either splits or dividends.... stock split historymind medicine10 yearmindmedmacrotrends https://www.prnewswire.com/news-releases/mindmed-acquires-opioid-addiction-drug-candidate-based-on-the-natural-psychedelic-ibogaine-300918912.html Mindmed Acquires Opioid Addiction Drug Candidate Based on the Natural Psychedelic Ibogaine /PRNewswire/ -- Mind Medicine, Inc. ("Mindmed"), the leading neuro-pharmaceutical company focused on discovering and developing medicines based on... opioid addictiondrug candidate https://www.fool.com/investing/2022/08/18/why-mind-medicine-mindmed-stock-is-crushing-it-tod/ Why Mind Medicine (MindMed) Stock Is Crushing It Today | The Motley Fool why mind https://investingnews.com/mindmed-announces-the-addition-of-stanford-university-neuroscientist-as-chair-of-the-scientific-advisory-board/ MindMed Announces the Addition of Stanford University Neuroscientist as Chair of the Scientific... Mar 8, 2022 - Dr. Robert C. Malenka is the Pritzker Professor of Psychiatry and Behavioral Sciences, Director of the Nancy Pritzker Laboratory and Deputy Director of the Wu... stanford universitymindmedannouncesaddition https://thehustle.co/04302021-mindmed The Nasdaq gets groovy with the listing of psychedelics biotech firm MindMed MindMed is sponsoring several clinical trials to bring psychedelics and hallucinogens (LSD, MDMA) to the market. biotech firmnasdaqgetsgroovy https://www.newswire.ca/news-releases/mindmed-strengthens-board-with-appointment-of-two-new-independent-directors-878184695.html MindMed Strengthens Board with Appointment of Two New Independent Directors /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to... two newmindmedboardappointmentindependent https://www.nasdaq.com/events/mindmed-rings-the-opening-bell MindMed Rings the Opening Bell | Nasdaq ABOUT THIS EVENT MindMed (Nasdaq: MNMD), a leading psychedelic medicine biotech company, rings the Nasdaq Opening Bell remotely from across the country. the openingmindmedringsbellnasdaq https://www.businesswire.com/news/home/20230504005909/en/MindMed-Reports-First-Quarter-2023-Financial-Results-and-Business-Highlights MindMed Reports First Quarter 2023 Financial Results and Business Highlights MindMed today reported its financial results for the quarter ended March 31, 2023. first quarter2023 financialmindmedreportsresults https://www.macrotrends.net/stocks/charts/MNMD/mind-medicine-mindmed/market-cap Mind Medicine (MindMed) Market Cap 1970-1969 | MNMD | MacroTrends Mind Medicine (MindMed) market cap history and chart from 1970 to 1969. Market capitalization (or market value) is the most commonly used method of measuring... mind medicinemarket capmindmed19701969 https://www.fiercebiotech.com/biotech/mindmed-links-lsd-reduced-anxiety-phase-2b-plots-pivotal-trials MindMed links LSD to reduced anxiety in phase 2b, plots phase 3 Dec 14, 2023 - Patients in some of the phase 2b dose cohorts experienced reductions in anxiety that persisted through the four-week trial. in phasemindmedlinkslsdreduced https://natlawreview.com/article/legalizing-lsd-fda-says-mm-hmm-mm120 FDA Grants Therapy Designation to MindMed's Proprietary LSD Food and Drug Administration FDA grants breakthrough therapy designation to MindMed's LSD-like substance MM120 for the treatment of generalized anxiety disorder fdagrantstherapydesignationmindmed https://www.businesswire.com/news/home/20250424648886/en/MindMed-to-Report-First-Quarter-2025-Financial-Results-on-May-8-2025 MindMed to Report First Quarter 2025 Financial Results on May 8, 2025 Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidate... 2025 financial resultsfirst quartermindmedreport https://www.fool.com/investing/2022/09/08/why-mind-medicine-mindmed-stock-tumbled-this-week/ Why Mind Medicine (MindMed) Stock Tumbled This Week | The Motley Fool Sep 8, 2022 - MindMed's stock has been moving lower ever since its reverse split last month. why mindthis weekthe motleymedicinemindmed https://www.biospace.com/mindmed-announces-transitions-to-management-team MindMed Announces Transitions to Management Team - BioSpace Dec 29, 2021 - Bradford Cross , Chief Technology Officer to transition; Don Gehlert , PhD, Chief Scientific Officer to transition to Senior Scientific Advisor. to managementmindmedannouncestransitionsteam https://www.biospace.com/mindmed-to-host-conference-call-and-webcast-to-discuss-first-quarter-2024-financial-results-and-provide-business-update MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and... May 2, 2024 - Mind Medicine announced today that it plans to host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to provide a corporate update and review the... https://definiumtx.com/ Definium Therapeutics (Formerly MindMed) | Psychedelic Medicine May 7, 2026 - Definium Therapeutics (Formerly MindMed) is forging a new era in psychiatry by harnessing the full therapeutic potential of psychedelic medicine. definium therapeuticsformerlymindmedpsychedelicmedicine https://www.newswire.ca/news-releases/mindmed-announces-50-million-bought-deal-public-offering-847758161.html MindMed Announces $50 Million Bought Deal Public Offering /CNW/ - Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) ("MindMed" or the "Company"), the leading neuro-pharmaceutical company for psychedelic... bought dealmindmedannounces50million https://investingnews.com/news/psychedelics-investing/mindmed-increases-cash-on-hand-to-cad-205.2m-closes-financing-of-cad-19.5m/ MindMed Increases Cash on Hand to CAD $205.2m , Closes Financing of CAD $19.5m | INN Apr 25, 2023 - NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Mind Medicine (MindMed) Inc. (NEO: MMED, OTCQB: MMEDF, DE:...